Hünnemeyer A - Search Results

1

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Litzenburger T, Steffgen J, Benediktus E, Müller F, Schultz A, Klein E, Ramanujam M, Harcken C, Gupta A, Wu J, Wiebe S, Li X, Flack M, Padula SJ, Visvanathan S, Hünnemeyer A, Hui J. Litzenburger T, et al. Among authors: hunnemeyer a. Br J Clin Pharmacol. 2021 Apr;87(4):1824-1838. doi: 10.1111/bcp.14571. Epub 2020 Nov 20. Br J Clin Pharmacol. 2021. PMID: 32986868 Free PMC article. Clinical Trial.

2

Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

Hauns B, Hermann R, Hünnemeyer A, Herzog R, Hauschke D, Zech K, Bethke TD. Hauns B, et al. Among authors: hunnemeyer a. J Clin Pharmacol. 2006 Oct;46(10):1146-53. doi: 10.1177/0091270006291621. J Clin Pharmacol. 2006. PMID: 16988203 Clinical Trial.

3

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.

Böhmer G, Gleiter CH, Hünnemeyer A, Lahu G, Bethke TD. Böhmer G, et al. Among authors: hunnemeyer a. Int J Clin Pharmacol Ther. 2011 Jul;49(7):451-60. doi: 10.5414/cp201535. Int J Clin Pharmacol Ther. 2011. PMID: 21726496 Clinical Trial.

4

Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

Nassr N, Lahu G, Hünnemeyer A, von Richter O, Knoerzer D, Reutter F, Zech K, Hermann R. Nassr N, et al. Among authors: hunnemeyer a. J Clin Pharmacol. 2007 May;47(5):660-6. doi: 10.1177/0091270006297920. Epub 2007 Mar 20. J Clin Pharmacol. 2007. PMID: 17374735 Clinical Trial. No abstract available.

5

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

Bethke TD, Hartmann M, Hünnemeyer A, Lahu G, Gleiter CH. Bethke TD, et al. Among authors: hunnemeyer a. Int J Clin Pharmacol Ther. 2011 Aug;49(8):491-9. doi: 10.5414/cp201556. Int J Clin Pharmacol Ther. 2011. PMID: 21781649 Clinical Trial.

6

The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Böhmer GM, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R. Böhmer GM, et al. Among authors: hunnemeyer a. J Clin Pharmacol. 2009 Apr;49(4):389-97. doi: 10.1177/0091270008330980. J Clin Pharmacol. 2009. PMID: 19318692 Clinical Trial.

7

Pharmacokinetic evaluation of roflumilast.

Lahu G, Nassr N, Hünnemeyer A. Lahu G, et al. Among authors: hunnemeyer a. Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1577-91. doi: 10.1517/17425255.2011.632409. Epub 2011 Nov 8. Expert Opin Drug Metab Toxicol. 2011. PMID: 22059647 Review.

8

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, McCracken N, Facius A. Lahu G, et al. Among authors: hunnemeyer a. Clin Pharmacokinet. 2010 Sep;49(9):589-606. doi: 10.2165/11536600-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20690782

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters